The Quantellect read.As of Nov 19, 2026, 20 active firms cover Eli Lilly and Company: 19 rate it Buy or better, 0 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. Targets span $940.00 to $1600.00, a moderate spread. The average target of $1346.63 sits 1% below the current $1360.13. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 18 to 19 over recent months. On the fundamentals, the Street sees consensus EPS building from about $10.94 next quarter toward $50.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 active firms
Buy
Strong Buy00%
Buy1995%
Neutral00%
Sell15%
Strong Sell00%
Based on 20 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$1346.63
-1.0% downside
Average target across 19 active firms as of Nov 19, 2026 vs $1,360.14 current
Highest Target$1600.00
Average Target$1346.63
Lowest Target$940.00
Detailed analyst forecasts for LLY
Showing 1–20 of 20 named analysts shown · 20 active firms in the rating projection
As of Nov 19, 2026, 19 of 20 active firms rate LLY a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LLY EPS & revenue forecast
EPS · NEXT QUARTER
$10.94
Range $10.31 – $11.63 · 6 analysts · +28% YoY
Next period, 6 analysts expect Eli Lilly and Company to earn $10.94 a share (range $10.31 – $11.63), versus $8.55 a year earlier. Full-year consensus is $35.47, growing to $50.80 the year after.
REVENUE · NEXT QUARTER
$23.5B
Range $22.6B – $24.6B · 6 analysts · +19% YoY
Revenue is expected to reach $23.5B (range $22.6B – $24.6B), +18.9% year-over-year. Full-year consensus is $91.7B, rising to $106.5B next year.
Top analysts covering Eli Lilly and Company
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LLY.
#1
Jason Gerberry
B of A Securities · Rank #160
Buy
$1497.00+10.1% to target
Overall win rate
47%
+ Follow
#2
Terence Flynn
Morgan Stanley · Rank #222
Buy
$1596.00+17.3% to target
Overall win rate
36%
+ Follow
#3
CS
Chris Schott
JP Morgan · Rank #287
Buy
$1650.00+21.3% to target
Overall win rate
41%
+ Follow
#4
Mohit Bansal
Wells Fargo
Buy
$1500.00+10.3% to target
Coverage
—
+ Follow
#5
Carter Gould
Cantor Fitzgerald
Buy
$1440.00+5.9% to target
Coverage
—
+ Follow
LLY stock forecast FAQ
What is LLY's average 12-month price target?+
The 19 active firms with a live target average $1346.63 for Eli Lilly and Company over the next 12 months, ranging from a $1600.00 high to a $940.00 low, as of Nov 19, 2026.
Is LLY stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 20 active firms as of Nov 19, 2026, 19 rate it Buy or Strong Buy, 0 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for LLY?+
The Street-high target is $1600.00 (Citigroup), and the Street-low is $940.00 (HSBC). The average of all 19 active-firm targets is $1346.63.
How many active Wall Street firms cover LLY?+
20 active firms have a recognized rating on Eli Lilly and Company as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LLY?+
Among analysts who currently cover LLY, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #160). Their current call is Buy with a $1497.00 target.
What is Eli Lilly and Company's projected EPS for next quarter?+
The consensus estimate is $10.94 per share (range $10.31 – $11.63) across 6 analysts. Full-year EPS is projected at $35.47, rising to $50.80 the following year.
How much revenue is Eli Lilly and Company expected to report next quarter?+
Consensus revenue is $23.5B (range $22.6B – $24.6B). Full-year revenue is projected at $91.7B, growing to $106.5B next year.
Have analysts been upgrading or downgrading LLY lately?+
As of Nov 19, 2026, 19 of 20 active firms rate LLY a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LLY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.